Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

If you are wondering whether Pfizer at around $25 a share is a value trap or a genuine opportunity, this breakdown will help you decide whether it deserves a spot on your watchlist right now. Despite ...

Pfizer (PFE) just laid out a 2026 outlook that underwhelmed the market, with lower expected earnings and revenue as COVID-19 ...

Within Pfizer’s large product portfolio, several mixed product trends led to overall 4% year-over-year growth, with particularly strong sales in vaccines and cancer drugs offsetting declines from ...

Pfizer's stock has dropped due to a decline in revenues post-COVID, presenting a value investment opportunity. The company still generates significant gross profit and has a strong revenue growth rate ...

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

Pfizer (NYSE: PFE) has been around for 175 years, selling a wide range of drugs in various treatment areas over time. But this pharma giant truly became a household name a few years ago. Pfizer made ...

Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71 in December 2021, driven by its COVID-19 ...

Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer Inc. and is seeking to spur a turnaround of the struggling pharmaceuticals giant, according to a person familiar with ...

ALEXANDRIA, VA (June 17, 1999)-- Pfizer (NYSE: PFE) is trading at 38 times its trailing 12-month earnings per share, 40 times 1999 estimates, and 33.9 times the year 2000 EPS guess. The largest ...